Streetbeat News

ESLA

Estrella Immunopharma, Inc.

https://www.estrellabio.com

Industry

Biotechnology

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

In Monday's pre-market session, several healthcare stocks experienced significant movements. EyePoint Pharmaceuticals (EYPT) saw a dramatic increase of 378.8%, while Alterity Therapeutics (ATHE) and Lucy Scientific Discovery (LSDI) also posted substantial gains. On the downside, NexImmune (NEXI) and Panbela Therapeutics (PBLA) experienced notable declines, along with other companies such as Sana Biotechnology (SANA) and Vivos Therapeutics (VVOS).

Portfolio Pulse from Benzinga Insights

December 04, 2023 | 1:06 pm

In Friday's after-market session, several healthcare stocks experienced significant movements. Mira Pharmaceuticals, TC BioPharm, Panbela Therapeutics, Estrella Immunopharma, Bio-Path Holdings, and MyMD Pharmaceuticals were among the gainers, with increases ranging from 7.14% to 9.2%. Conversely, Impel Pharmaceuticals, Avenue Therapeutics, Cyclacel Pharmaceuticals, Alaunos Therapeutics, Evoke Pharma, and Scholar Rock Holding were the losers, with their stock prices falling between 7.07% and 20.9%.

Portfolio Pulse from Benzinga Insights

November 24, 2023 | 9:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.